Eocene Ltd(EOCN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 29 at 4:01 AM ET (Korea 9/29 17:01)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -13.81 | Insider Own | 2.43% | Shs Outstand | 1.0M | Perf Week | 3.71% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 80.98% | Insider Trans | - | Shs Float | 1.0M | Perf Month | -15.69% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -3.06 | Inst Own | 3.95% | Short Float | 1.1% | Perf Quarter | -20.52% |
| Income | -0.01B | P/S | - | EPS this Y | 40.32% | Inst Trans | 0.26% | Short Ratio | 0.18 | Perf Half Y | -10.11% |
| Sales | 0.00B | P/B | 0.29 | EPS next 5Y | 52.34% | ROA | -55.03% | Short Interest | 0.01M | Perf YTD | -39.54% |
| Book/sh | 12.72 | P/C | 0.33 | EPS past 3/5Y | 73.46% 60.33% | ROE | -68.21% | 52W High | -72.5% ($13.20) | Perf Year | -67.59% |
| Cash/sh | 10.94 | P/FCF | - | Sales past 3/5Y | - | ROIC | -88.73% | 52W Low | 11.11% ($3.27) | Perf 3Y | -93.27% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 68.55% | Gross Margin | - | Volatility(W/M) | 6.19% 9.59% | Perf 5Y | -99.92% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.36 | Perf 10Y | -99.95% |
| Dividend Ex-Date | - | Quick Ratio | 4.16 | EPS Q/Q | 43.43% | Profit Margin | - | RSI (14) | 43.38 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.16 | Sales Q/Q | - | SMA20 | -3.99% ($3.78) | Beta | 0.65 | Target Price | $96 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/07/30 | SMA50 | -12.83% ($4.16) | Rel Volume | 0.06 | Prev Close | $3.63 |
| Employees | 6 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 8.33% - | SMA200 | -28.01% ($5.04) | Avg Volume(3M) | 0.06M | Price | $3.63 |
| IPO | 2014/3/13 | Option/Short | No/Yes | Trades | 115 | Volume | 3,889 | Change | - |
Eocene LtdEOCN | NASD | Biotechnology 🩺 이스라엘에 본사를 둔 소화기 질환 중심의 의료기기·바이오테크 기업입니다. 간 질환 신약 개발사로 출발해 소화기 분야로 사업 축을 옮겼고, 자회사 콜로스판을 통해 대장 수술 후 문합부를 보호하는 의료기기를 상업화하는 단계에 있습니다. 시총 기준으로는 마이크로캡에 속합니다.
Over the past 1 year, on the lower side
73% below its 1-year high.
Traded less than usual That is 6% of its average volume.
EOCN has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +40.3% this year.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.9%. The S&P 500 did +77% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 4.0%.
Tap to view numbers
It ranks #562 of 592 in the industry
Based on market cap of $4M.
FAQ
What kind of company is EOCN?
EOCN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of EOCN?
The market cap of EOCN is approximately $4M, ranking 5,748 within its sector.
What is the 52-week high and low for EOCN?
EOCN has recorded a 52-week high of $13.20 and a low of $3.27.
